Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $6.00 | Change: +$0.08 | %Change: +1.35%
Volume: 35,999 | Day High/Low: 6.00/5.79 | 52 Week High/Low: 10.36/2.50
View modes: 
0 stars

RE:RE:RE:RE:Profits from P2 sales

Fopr comparison, Cipher will do about $12 million in net profits this year and its market cap is $320 million. The reason ? Nuvo has yet to be promoted in any real way by  professional promoters...read more
0 stars

Seeking Alpha Article May 26th 2015

http://seekingalpha.com/article/3211106-nuvos-revamped-strategy-should-unlock-significant-value?auth_param=13hiok:1ambic2:57a304f98a06d2163b1d5b657f0f20d4&uprof=45&dr=1  rate and reply
0 stars

Horizon

Presents at Jefferies 2015 Global Healthcare Conference on June 4. Hopefully a higher prescription count is shown then the last number we have from Nuvo which was nothing short of outstanding. Led me...read more
0 stars

Remember this word.

.. . . .MERRY CHRISTMAS TO ALL!!  rate and reply
1 star

Name your Price

Cash & Investment = 58.33 mil / 10.77 OS  = $5.41 Properties = ? IP= ? Where is this stock heading??????? Merry Christmas to all who took their position on this late drop.  rate and reply
1 star

RE:RE:RE:Profits from P2 sales

To complete my former post, Nuvo will pay no tax on this $8 million, it will gain on interest ( about $500,000) rather than pay ( it has no debt ) , depreciation and amort are neglible. So the $8...read more
5 stars

Phase 3 -- sprains, strains, and sports injuries

This strikes me as a valuable direction for P3 to head (in addition to OA of the knee, etc.). Anecdotal reports going back nearly 20 years show that Pennsaid often has been used for sprains, strains,...read more
0 stars

RE:RE:Profits from P2 sales

A couple of comments on this issue and Zacks report. First, HZNP reports its revenues as NET sales. This makes Zacks 90% erroneous. The mark up is 34%. Secondly, Nuvo sells in USD and makes money on...read more
0 stars

RE:RE:Comment and a question

Sprains...strains and sport injuries require anti inflammatory meds. P2 contains the only delivery system DMSO which also buy itself has been used for years for inflammation. I use Pennsaid, and I...read more
5 stars

RE:Comment and a question

Recent excerpt: "I just want to make sure you, and others here understand that the upcoming Phase 3 trial in Germany is not based on the same indication as the previous trials or the US indication...read more
0 stars

RE:RE:RE:Profits from P2 sales

overflowing said:"Do you have any thoughts on the Zacks revenue estimate for Q2?  Napodano is estimating revenue of $3.8 million for the quarter for the entire company.  I'm trying to find a reason...read more
0 stars

RE:RE:RE:Profits from P2 sales

Thank you. I noticed the revenue and COS numbers did not seem to make a whole lot of sense but without understanding where the numbers came from or the methodology it is difficult to say. Is it...read more
0 stars

Comment and a question

Shouldn't we at least contemplate potential Revenue from a very large country (population wise) based on the below?  (Company news release) NovaMedica Pennsaid 2% Clinical Study in Russia...read more
0 stars

RE:RE:Profits from P2 sales

Great Post C99.  These are my thoughts and interpretations exactly.   Do you have any thoughts on the Zacks revenue estimate for Q2?  Napodano is estimating revenue of $3.8 million for the quarter...read more
0 stars

RE:RE:RE:Are we at $6.50 yet

Would be much happier now if we had not gone thru with the reverse split ..... oh how my .60 cents a share would look like today.......Holly Moly  rate and reply
5 stars

RE:Profits from P2 sales

Nuvo earned $1.2 million in Q1, from sales of about 32,000 bottles. Its roughly $40 per bottle, after all costs but interest and taxes. That $1.2 million refers to P2% product revenues. There are...read more
0 stars

RE:Nice increase off the lows

Santa Clause is coming to town.  rate and reply
0 stars

RE:RE:Are we at $6.50 yet

getting closer & closer..... :) Hope you're happy now Geos571  rate and reply
0 stars

Nice increase off the lows

Anyone taking profits yet or will you ride this out until the end again?  rate and reply
0 stars

RE:Profits from P2 sales

Pretty good numbers. Those profits should not only cover the costs of the two drug studies in 2015 but might also add to the cash position.  rate and reply